Biogen Avonex Patient Satisfaction Claim Draws Objection From FDA
Executive Summary
FDA is directing Biogen to stop making a patient satisfaction claim that the agency believes is misleading
You may also be interested in...
Rebif Promos Need More Risk Information, FDA Says, Citing Web, Print Ads
Serono needs to include more risk information in its Rebif promotions, FDA said in citing website and journal advertisements for the multiple sclerosis product
Rebif Promos Need More Risk Information, FDA Says, Citing Web, Print Ads
Serono needs to include more risk information in its Rebif promotions, FDA said in citing website and journal advertisements for the multiple sclerosis product
FDA Cites Avonex Comparative Promotions; Biogen Challenges Findings
FDA is asking Biogen to stop using the words "short- term" and "long-term" in promotional materials comparing its multiple sclerosis therapy Avonex (interferon beta-1a) with Serono's Rebif (interferon beta-1a)